Genomic testing for localized prostate cancer: an update

A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …

IL-35 levels in the diagnosis and prognosis of prostate cancer

A new paper by a group of Chinese researchers has suggested that levels of a biochemical called interleukin-35 (IL-35) in blood plasma may offer evidence of the presence of prostate cancer and do so significantly better than PSA levels (particularly for men with PSA levels of between 4 and 10 ng/ml). … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

Can the Decipher test accurately project risk for metastasis post-surgery?

A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …

Cancer tissue subtypes and prostate cancer prognosis

A newly published article in JAMA Oncology is asking whether there is a completely different way to look at how to classify prostate cancer tissue types and correlate such classification to responses to treatment using certainly classes of drugs. … READ MORE …

Testing for AR-V7 “validated” in men with CRPC

According to an article yesterday on Cancer Therapy Advisor, testing for circulating tumor cell (CTC)-based androgen receptor splice variant-7 (AR-V7) has now been validated as a prognostic test for men with castration-resistant prostate cancer (CRPC) receiving hormone therapy. … READ MORE …

Another research team, and another micro-RNA …

Last week we mentioned that one specific form of micro-ribonucleic acid (miRNA) may be usable in the development of a drug or drugs to stop the process of metastasis in men with high-risk forms of prostate cancer. Another recent study goes one step further than that. … READ MORE …